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ABSTRACT
The pregnane X receptor (PXR or SXR; NR1I2) is a member of the nuclear receptor
superfamily. It activates the transcription of a large network of genes including
cytochrome P450 (CYP) and Mdr1 which play critical roles in chemicals metabolism and
transportation. Induction of CYPs contributes to adverse drug-drug interactions. Nontoxic, PXR-specific antagonists will be valuable in attenuating the adverse drug-drug
interaction which is the cause of many treatment failures in clinic. However, few hPXR
antagonists were reported particularly the specific ones. In this thesis a reporter gene
assay was used to study the specificity of hPXR antagonists from a panel of compounds
that have been previously indentified as non-toxic hPXR antagonists.
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Chapter 1. Introduction
Brief Overview on PXR
Mouse Pregnane X receptor (PXR or SXR; NR1I2), a member of the nuclear receptor
(NRs) superfamily [1-3], was first cloned and identified in 1998 [4]. The human PXR
(hPXR) was found subsequently and named steroid and xenobiotic receptor (SXR) or
pregnane-activated receptor (PAR) [5, 6].
PXR is composed of four independent but interacting functional modules (Figure 1-1),
which include, from N-terminus to C-terminus, the modulator domain, the DNA-binding
domain (DBD), the hinge region and the ligand-binding domain (LBD) [7]. Among these
domains, DBD mediates the sequence-specific binding to the “response element” of its
target gene while LBD mediates the ligand-binding, dimerization to other NRs or
homodimerization and ligand-independent repression [8].
PXR has at least three isoforms, PXR.1, PXR.2 and PXR.3. PXR.1 is the most
abundantly expressed isoform in human tissue. It can be activated by structurally diverse
lipophilic ligands. PXR.2 mRNA which represents 6.7% of total PXR mRNA transcripts
is 111 nucleotides shorter than PXR.1, resulting in a deletion of 37 amino acids from the
PXR LBD. PXR.3 is 41 amino acids shorter than PXR.1 because the 123 nucleotide
region located in the putative LBD is lost. Due to the lack of the 41 amino acids, PXR.3
has a more restricted activation profile than PXR.1 [4]. For example, dexamethasone,
dexamethasone-t-butyl-acetate, dexamethasone-21-acetate and the pregnenolone
derivative 6,16α-dimethyl pregnenolone can activate PXR.1. However, among those
steroids, only dexamethasone-t-butyl-acetate is able to activate PXR.3. Homologous
comparisons of PXR.3 with different members of nuclear receptors indicate that PXR is
most like Xenopus laevis orphan nuclear receptor 1(ONR1) and mammalian vitamin D
receptor (VDR) [9, 10].
Both PXR.1 and PXR.2 are highly expressed in liver and intestine of embryo and
adult, and are expressed at a lower level in adult kidney and stomach, but are
undetectable in other organs [4, 11]. This specific distribution of PXR is highly correlated
to its versatile functions in regulating dynamic metabolism of a large number of
endogenous or exogenous nutrients, drugs or other chemicals, because liver and intestine
are the main organs where many xenobiotics and endobiotics are digested, absorbed, and
selectively eliminated [11].
Functions of PXR
Generally speaking, PXR can be regarded as an internal sensor for the alterations of
xenobiotics and endobiotics. Upon binding with diverse natural or synthesized ligands, it
will form herterodimers with retinoid X receptor (RXR). PXR and RXR heterodimer then
will probe and bind to the PXR response elements that are located in the 5’ end of the
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Figure 1-1. Schematic representation of hPXR multi-domain structure. hPXR has a
multi-domain structure which includes a modulatory A/B domain, the DNA-binding
domain (C domain), the hinge D domain and the ligand-binding domain (E domain)
which contains a shallow activation function 2 (AF-2) surface essential for liganddependent interactions with transcriptional coregulators.
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PXR target genes (Figure 1-2). PXR can either promote or block the transcription of
targeted genes which include but are not limited to P450s from CYP3A and CYP2B,
transporters such as P-glycoprotein, multidrug resistance-related protein-3, and organic
anion transporting polypeptide-2 (OATP2) [12-15]. PXR is so important in regulating
metabolic enzymes and transporters that it inevitably is able to affect the speed at which
different drugs are digested, absorbed, and eliminated from the body. If different drugs
are used at the same time and some drugs happen to be PXR ligands with high affinities,
drug-drug interactions will happen. Drug-drug interactions could accelerate dynamics of
the drugs which are the substrates of PXR targeted genes-encoded enzymes and lead to
adverse effects including death.
Three examples are given here to demonstrate the roles of PXR in drug-drug
interactions. The first instance is Rifampicin, a drug for long term tuberculosis treatment
[16]. Moreover, Rifampicin is a human PXR ligand as well. As mentioned previously,
PXR can regulate CYP3A which can metabolize a lot of drugs which include anti-HIV
protease inhibitors, oral contraceptives, and midazolam [17-19]. The second example is
the drug-drug interactions between St John’s Wort, an old herbal medicine for mental
disorders and nerve pain, and Cyclosporine, an immunosuppressant used in patients who
received organ transplantation to prevent organ rejection. It has been found that
components of St John’s Wort contain multiple PXR ligands so that CYP3A activated by
PXR will speed up cyclosporine metabolism and will lead to transplantation failure [20].
The third example is that isoniazid and 3-methylcholanthrene can accelerate the
metabolism of Acetaminophen (APAP) and cause accumulation of the alkylating
metabolite N-acetyl-p-benzo-quinone imine (NAPQI) and result in liver damage in a
PXR-dependent manner [21-23]. Recently, several traditional Chinese medicine (TCMs)
have also been implicated in drug-drug interactions [24, 25].
In addition to the xenobiotic functions such as drug-drug interactions discussed
already, PXR also have important roles in the endobiotic dynamics. Such endobiotic
associated functions include regulating bile acid detoxification and cholestasis, bilirubin
detoxification and clearance, adrenal steroid homeostasis and drug–hormone interactions,
lipid metabolism, inflammation and inflammatory bowel disease, bone homeostasis, and
retinoic acid metabolism, all of which functions as intensively reviewed[11, 26]. PXR
activation also up-regulates other drug transporter genes, like Mdr1, Mrp2 and Mrp3 [27].
Not only does PXR regulate the expression of so many genes, it also interplays with
many other nuclear receptors and affects the transcriptional activity thus the expression of
their target genes. The nuclear receptors that crosstalk with PXR include FXR, GR, CAR,
VDR, etc.
Genetic Variation of Human PXR
The hPXR gene contains 9 exons, and all exons except exon1 contain coding regions. It
is located on chromosome 3q12q13.3, with 38 kb length [28]. Similar to mouse PXR,
hPXR has a few variants. In addition to the three main variants, hPXR.1, hPXR.2 and
hPXR.3, there are 7 more splice variants with low expression frequency and with
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Figure 1-2. Schematic representation of hPXR function. With ligand binding, PXR
dimerizes with RXR. RXR/PXR heterodimer binds to the response element of target
genes, like CYP3A, CYP2B and MDR1 and regulates their transcription.
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unknown function [29].
In addition to the splice variants, genetic variations also were found in the hPXR exon
coding regions. Heretofore, there are 227 SNPs have been found [26]. Among all the
exons, so far exon4, encoding the C-terminal portion of the DBD and part of the Nterminal portion of the LBD, has most identified SNPs. Some SNPs such as P27S can
affect protein function by either change in hydrophobicity or creation of a serine
phosphorylation site [28, 30]. The variations become further complicated when genetic
variants are also found in the promoter region and other non-coding regions of hPXR.
Probably, those individual variations could account for the different dynamics patterns in
different patients, when identical drugs were used.
PXR Antagonists
Due to the presence of drug-drug interactions, PXR antagonists seem to be the
promising small molecules that could block PXR-mediated drug-drug interactions, and
optimize the efficacy of therapeutics. Designing efficient antagonists against PXR are
becoming a trend in clinical medicine. Recently, PXR gene activity has been detected in
endometrial cancer but not normal tissues, highlighting the oncogene-like roles of PXR in
tumorigenesis. This notion is further supported by the expression of PXR in prostate
cancer, breast cancer and osteosarcoma tissues, in addition to tumor cell lines [31-34]. In
prostate cancer cell line PC-3 and endometrial cancer cell line HEC-1, knocking down
PXR expression by RNA interference (RNAi) has been shown to be a useful approach to
down-regulate CYP3A4 and MDR1. The diminishment of PXR-mediated expression of
CYP3A4 and MDR1 significantly increase the therapeutic sensitivities to anticancer
agents such as paclitaxel and cisplatin, with corresponding reduced drug resistance, as
already perfectly reviewed [35].
So far, database of PXR antagonists is expanding. Those antagonists include but are
not limited to ET-743, some polychlorinated biphenyls, ketoconazole, fluconazole,
enilconazole, sulforaphane and coumestrol [36-41]. However, it is still elusive whether
those antagonists, like ET-743, could directly bind to PXR or not. Additionally,
ketoconazole was shown to function as a wide-range inhibitor for many nuclear receptors
including PXR, by disrupting NR-co-activator interaction. In contrast, as a PXR
antagonist, Sulforaphane (SFN) inhibits PXR function by directly binding to PXR [40].
Note that SFN still has PXR antagonist independent functions such as histone deacetylase
inhibition and Phase II enzymes induction.
The mechanisms through which most current antagonists inhibit PXR function have
been proposed. The antagonists will bind to the outer surface of PXR at the AF-2 domain
and compete with PXR required co-activators [42]. Recently, computational methods
have been used for discovering new antagonists [43]. Because of the promiscuity of
potential PXR ligands discussed previously, it is difficult to design effective antagonists
targeting the PXR ligand binding pocket. Therefore, the high-through-put screening of a
huge pool of pre-generated chemical compounds seems to be a more efficient way to
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identify some specific PXR antagonists [35]. However, no specific PXR antagonist has
been identified. Testing the overall effects of those antagonists on PXR functions in vivo
or whether they really can improve the therapeutic efficacy will rely on the mouse models
to be discussed.
Crosstalk between PXR and other Nuclear Receptors
There are 48 human nuclear receptors have been identified so far (Figure 1-3). These
nuclear receptors work in concert with each other in the regulation of gene transcription.
PXR and some other nuclear receptors work together and form a complex network to
coordinately regulate metabolism of both xenobiotics and endobiotics, thus protecting
from diverse groups of adverse chemicals [27]. There are a few types of coordination
among PXR and other nuclear receptors. First, PXR functions with other nuclear
receptors to regulate the same target genes. For example, FXR and PXR together can
form a feedback mechanism to induce CYP3A4 gene expression which in turn can
regulate bile acid metabolism, thus protecting hepatocytes from toxicity of bile acid. This
is further supported by the fact that lithocholic acid (LCA) still, to some extent, can
induce CYP3A4 gene expression in a PXR knockout mouse [44, 45]. Second, activities
of PXR can be inhibited by target genes of other nuclear receptors. For example, small
heterodimer partner (SHP) can inhibit transcriptional activity of PXR in a dose dependent
manner [46]. Third, activities of PXR can be boosted by other genes. For instance,
hepatocyte nuclear factor-4 alpha (HNF-4 alpha) is able to induce expression of PXR,
which is further supported by the phenotypes of the HNF-4 alpha mutant mouse model
[47]. In addition to the networks discussed above, PXR also interacts with Liver X
Receptor (LXR), Glucocorticoid Receptor (GR), constitutive androstane Receptor (CAR)
and Vitamin D Receptor (VDR) [27].
PXR Mutant Mouse Models
Due to the genomic similarities between mouse and human, mouse is a good animal
model to elucidate the roles of many genes including PXR. So far, there are two kinds of
PXR mutant models. Each kind has two different lines. The first kind is the PXR knockout mouse. Because the PXR-null mice are viable, fertile and have no obvious
developmental deficiencies, it suggests that PXR is not essential for mouse development
or physiological homeostasis [48, 49]. However, in contrast with the PXR wild type
mice, PXR-null mice are no longer responsive to PXR ligands such as PCN.
Because of the different ligand binding domain (LBD) of PXR between mouse and
human, some rodent robust PXR ligands, however, are weak for human PXR, and vice
versa [50]. This will preclude further probing of PXR agonist or antagonist effects using
mouse models for preclinical implications. To by pass this problem, three PXR
humanized mouse models were generated. Those humanized PXR mutant mice will no
longer respond to the rodent-specific PXR ligand PCN. One is Alb-hPXR mice generated
by cDNA in which Alb-hPXR is restricted in liver [49]. The other is a bacterial artificial
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Figure 1-3. Phylogenetic tree of human nuclear receptors (from Wikipedia). There
are 48 known human nuclear receptors. PXR interplays with several other nuclear
receptors including CAR and VDR which belong to the same group as PXR, and those
from other groups, like GR, RXRα, RXRβ, FXR, PPARγ and LXR.
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chromosome (BAC) transgenic mouse line where PXR gene is under control of the
endogenous human PXR promoter [51]. The third one is the mouse line where human
PXR is fused to a viral VP16 coactivator, resulting in a constitutively active form of
human PXR [52]. The PXR-humanized mice have been shown to be useful models to
bypass the species differences in response to PXR ligands.
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Chapter 2. Materials and Methods
Reagents
Dulbecco's modified eagle medium (DMEM), phenol red-free DMEM, dialyzed FBS,
Recovery™ cell culture freezing medium, non-essential amino acids (NEAA), HEPES (1
M, pH 7.3), penicillin/streptomycin (antibiotics), sodium Pyrurate, Zeocin™,
Geneticin®, blasticidin, 0.05% trypsin/EDTA, GeneBLAzer® loading kit and
Dulbecco’s phosphate buffered saline (DPBS) without calcium and magnesium were
from Invitrogen. Matrigel™ matrix was from BD Biosciences. Charcoal treated FBS was
from Hyclone. Hygromicin B was from Roche. Dimethyl sulfoxide (DMSO) was form
Fisher. Dexamethasone, chenodeoxycholic acid (CDCA) and GW4064 were from Sigma.
Calcitriol (1α, 25-dihydroxyvitamin D3) was from Calbiochem. 9-cis-retinoic acid was
from Biomel. Rosiglitazone was form Sequoia. TO901317 was from Cayman Chemical.
Tissue culture flasks, 384 well, black-wall with clear flat bottom tissue culture treated
and Poly-D-Lysine surface plates were from Corning.
Equipment
Matrix WellMate with stacker; 384-channel VPrep® pipetting station; EnVision 2102
multilabel reader; Biomek® FXР laboratory automation workstation; 384-multichanel
pipetting head; 10H and 50H pin.
Cell Lines
GR-UAS-bla HEK 293T, VDR-UAS-bla HEK 293T, RXRα-UAS-bla HEK 293T,
RXRβ-UAS-bla HEK 293T, FXR-UAS-bla HEK 293T, PPARγ-UAS-bla 293-H, LXRαUAS-bla HEK 293T, LXRβ-UAS-bla HEK 293T cell lines were from invitrogen. All cell
lines except RXRα, RXRβ, and FXR were maintained in Matrigel™ matrix precoated
flasks in the humidified 37°С/5%CO2 incubator. Cell thawing, propagation and freezing
were performed as described in GeneBLAzer® cell-based assay protocol.
Mycoplasma Detection Assay
MycoAlert® mycoplasma detection kit was from Lonza. At every cell passage, after
cells were spun down 200 μl cell culture supernatant was taken and centrifuged at 200xg
for 5 min. 100 μl cleared supernatant was transferred into a white walled 96-well plate as
test sample. 100 μl of MycoAlert® reagent was added into the sample. After 5 min
luminescence was read and data was recorded as A. Then 100 μl of MycoAlert®
substrate was added into the well. After 10 min luminescence was read again and data
was recorded as B. B/A ratio was calculated. If B/A <1, then it’s negative, otherwise it is
positive (mycoplasma contaminated).
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Beta-lactamase Reporter Assay
Assays were performed as described below in the antagonist assay section. After
subtracting the average fluorescence intensity of both 460nm and 530nm emission from
the cell-free control wells, the 460 nm/530 nm ratio was calculated. For EC50
determination, the ratios were plotted against primary agonist concentration in log scale
and then analyzed using Prism software (GraphPad Software, Inc., San Diego, CA)
Sigmoidal dose-response equation with varying slope was used to fit the data and
generate EC50 value. For compound assay, the percentage of inhibition activity is
calculated as inhibition activity = 1- (test compound-negative control)/(positive control negative control)*100%. The percentage of inhibition activity is plotted against test
compound concentration in log scale using Prism one site competition. Z’ factor was
calculated for each assay plate using Z’ factor = 1-[(3*SDpos. + 3*SDneg.)/(avgpos.-avgneg.)].
The assays having Z’ factor of above 0.5 will be accepted.
Compound Profiling
Compounds were initially dissolved in DMSO (10 mM). 384-well master dilution
plates were made by serially one to three diluting across the plate, starting at 10 mM to
0.508 μM in DMSO. 384-multichanel pipetting head with 10H or 50H Pins were used to
transfer compound from the master dilution plate to assay plates by Biomek® FXР
laboratory automation workstation. 10H pin carries 25 nl liquid and 50H pin carries 50 nl
for each transfer.
Antagonist Assay
Cells were harvested at 80% confluence and then re-suspended in assay medium as
described in chapter 3. Certain concentrations of the cell suspension was dispensed into
384-well, black-wall, clear bottom assay plates. Plates were centrifuged at 1000 rpm for 1
minute to help cells attach to the bottom. After 30 min, test compounds were transferred
into to the plates using Biomek® FXР laboratory automation workstation. The primary
agonist was applied to stimulate cells after test compounds were transferred. DMSO was
used as a negative control of compound treatment. The primary agonist was used as a
positive control of compound treatment. Plates were then incubated in the humidified
37°С/5%CO2 incubator for 16 hours. LiveBLAzer substrate was loaded after plates were
cooled down to room temperature. After certain time incubation in the dark the plates
were read on EnVision 2102 multilabel reader for fluorescence intensity at 460 nm and
530 nm.
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Chapter 3. Determing the Specificity of hPXR Antagonists
Introduction
Of the 48 human nuclear receptors identified so far, several of them have been
demonstrated to interplay with PXR. The expression of PXR target gene thus is
controlled by many physiopathological parameters other than the transcriptional activity
of PXR. The nuclear receptors involved in functional crosstalk with PXR are
glucocorticoid receptor (GR), retinoid X receptor (RXR), farnesoid X receptor (FXR),
peroxisome proliferators-activated receptor (PPAR), liver X receptor (LXR). In addition,
vitamin D receptor (VDR) and constitutive androstane receptor (CAR) belong to the
same subfamily of NR as PXR and share many common features with PXR. They are
also involved in the signaling pathway of PXR target gene regulation.
Because of the interplay between PXR and these nuclear receptors they share many
modulators. Many antagonists of these nuclear receptors have been identified so far.
However, most of them are not specific. When a drug is administrated to antagonize one
nuclear receptor it often affects the activity of other nuclear receptors involved in other
signaling pathways as well. So, to identify specific antagonists for PXR is extremely
important in both clinical and basic research.
A panel of nuclear receptor cellular assays have been built by Invitrogen through
stably engineering expression of a fusion protein consisting of the target nuclear receptor
ligand binding domain (LBD) and Gal4 DNA binding domain (DBD) in a parental HEK
293 cell line containing the beta-lactamase reporter gene under transcriptional control of
an upstream activation sequence (UAS) (Figure 3-1). This reporter gene assay is able to
detect the functional response of a ligand or modulator would have on its receptor.
Compared with the traditional cell-based reporter gene assay which uses endogenous or
exogenous full-length receptors, GeneBLAzer eliminates the limitation of selectivity
because different nuclear receptors can bind to the same or similar response elements and
ligands [53].
In this assay when the ligand binds to the LBD of nuclear receptor the fusion protein
will bind to the UAS through the DBD of Gal4. This process will activate the
transcription of beta-lactamase, which will be expressed and secreted into the cytoplasm.
The protein expression level would be measured by reading the fluorescence intensity of
a fluorescent substrate which could be dissected by beta-lactamase. When excited the
substrate emits green light if it’s intact, blue light if it’s been cleaved (Figure 3-2).
In my experiment eight of the GeneBLAzer cell lines engineered with nuclear
receptors most functionally related to PXR were used to study the specificity of 92
previously identified PXR antagonists. These cell lines are GR-UAS-bla HEK 293T,
VDR-UAS-bla HEK 293T, RXRα-UAS-bla HEK 293T, RXRβ-UAS-bla HEK 293T,
FXR-UAS-bla HEK 293T, PPARγ-UAS-bla 293-H, LXRα-UAS-bla HEK 293T, LXRβUAS-bla HEK 293T cells.
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Beta-lactamase

NR LBD

L

Gal4 DBD
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HEK 293T

Figure 3-1. Schematic representation of GeneBLAzer nuclear receptor cell lines.
The cell stably expresses a fusion protein consisting of the target nuclear receptor ligand
binding domain (LBD) and Gal4 DNA binding domain (DBD). The fusion protein will
regulate the expression of beta-lactamase reporter gene which is under the control of an
UAS response element. When a ligand binds to the LBD of target nuclear receptor betalactamase will express and excrete out of the cell.
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Figure 3-2. Schematic illustration of FRET assay (Invitrogen protocol). The BLA
substrate has two fluoroprobes, coumarin and fluorescein. In the absence of bla
expression in the cell, the substrate remains intact and is capable of fluorescence
resonance energy transfer (FRET) and emission of green light. In the presence of bla
expression, the substrate is cleaved and FRET is disrupted resulting in emission of blue
light.
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Materials and Methods
Cell Culture
GR was cultured in DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25
mM HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml streptomycin, 150 μg/ml
hygromycin B and 80 μg/ml Zeocin. VDR was cultured in DMEM supplemented with
10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100
μg/ml streptomycin, 80 μg/ml hygromycin and 80 μg/ml Zeocin. RXRα and RXRβ were
cultured in DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25 mM
HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml hygromycin
and 100 μg/ml Zeocin; FXR was cultured in DMEM supplemented with 10% dialyzed
FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml
streptomycin, 100 μg/ml hygromycin and 100 μg/ml Zeocin. PPARγ was cultured in
DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3),
100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml hygromycin, 500 μg/ml
Geneticin and 1 mM sodium pyrurate. LXRα was cultured in DMEM supplemented with
10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100
μg/ml streptomycin, 80 μg/ml hygromycin and 80 μg/ml Zeocin. LXRβ was cultured in
DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3),
100 U/ml penicillin, 100 μg/ml streptomycin, 80 μg/ml hygromycin and 15 μg/ml
blasticidin.
All cells were maintained between 5% and 95% confluence. Flasks for culturing GR,
VDR, PPARγ, LXRβ were coated with 1X MatrigelTM matrix and incubated for 15 min
before plating.
For any assay process, cells were maintained in assay medium. GR cells were
harvested and re-suspended in 98% phenol red-free DMEM containing 2% charcoal
stripped FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml
streptomycin, 1 mM sodium pyrurate. PPARγ cells were maintained in 99% phenol redfree DMEM with 1% charcoal stripped FBS, 100 U/ml penicillin and 100 μg/ml
streptomycin. VDR, RXRα, RXRβ, FXR, LXRα and LXRβ cells were maintained in 98%
phenol red-free DMEM with 2% charcoal stripped FBS, 0.1 mM NEAA, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 1 mM sodium pyrurate.
Assay Optimization
All cells were tested negative for mycoplasma. Cells were resuspended in assay
medium for any assays. Four different concentrations of cells were plated. For GR and
VDR the cell number was 10k, 20k, 30k and 40k, for RXRα and RXRβ the cell number
was 5k, 10k, 20k and 30k per well. Cells were stimulated with maximum concentration
of their primary agonist. Plates were incubated at 37°С /5%CO2. After plates were cooled
down to room temperature different concentration of substrates were loaded. Plates were
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read for fluorescence intensity at interval times. Response ratio is calculated using the
460 nm/530 nm ratio of the stimulated wells divided by the unstimulated wells. A bar
graph was created using Response ratio against different assay conditions.
Agonist Dose-response
Ten different concentrations of agonist dilution were made by serially diluting across
the plate, starting at the maximum concentration for stimulation (Invitrogen validation
summary) decreasing in one third in 100% DMSO. Cells were seeded at the number per
well as determined in the section on assay optimization. The 10H pin tool which carries
25 nl liquid was used to transfer the agonist into the cell plates. Plates were incubated for
16 hours. Substrate was loaded and the plates were read at the condition determined as
described in the section on assay optimization. 460 nm/530 nm ratios for each well were
calculated, plotted and EC50 was determined as described in chapter two.
Compound Assay
Cells (with concentration determined in optimization) were dispensed by WellMate at
medium speed. Plates were centrifuged at 1000 rpm for 1 min to spin down the cells. The
50H pin tool was used to transfer from the compounds plate into the cell plates twice
(100 nl in total). Then agonist plate was transferred once (50 nl). Plates were incubated
for 16 hours. Substrate was loaded. Plates were read after the incubation time determined
in assay optimization. Data was analyzed as described in chapter two.
Results and Discussion
Assay Performance under Variable Conditions
To optimize the conditions, assays should be performed under different conditions
including cell numbers, compounds treatment time, DMSO concentration, and substrate
concentration, loading time and incubation time, plate types. According to the validation
data from the manufacturer all the cell lines performed the best for 16 hours incubation
after compounds were added. We used the same incubation time in our assay. Our assay
was performed in 384-well black wall, clear bottom plates with 25 μl assay volume and
6X substrate (5 μl) loading. Our system allowed us to use 50H pin which carries 50 nl of
liquid transferring twice from the stock into the 25 μl cells, which made the final DMSO
concentration 0.6%. According to the validation data provided by Invitrogen, it doesn’t
affect the assay performance when DMSO is below 1%.
In order to distinguish the compounds which can inhibit the activation of the
transcriptional activity of the nuclear receptor by its primary agonist from those that can’t
inhibit it, it is important to find the condition under which the signals generated by
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unstimulated wells (neg. control) and stimulated wells (pos. control) are different enough
that any minor effect on the transactivity will be observable. That is to say the higher
response ratio (pos. control⁄neg. control) the better.
Among the eight cell lines tested, GR had the highest response ratio of 15 to 22. The
signal produced by each well is quite consistent. The other three cell lines, VDR, FXR
and LXRα had a moderate response ratio of about 10 to 15. The signal varied especially
for FXR and LXRα. The response ratio of the other four cell lines, RXRα, RXRβ, PPARγ
and LXRβ was relatively low, at around 5 (Figure 3-3). This means that GR is a cell line
that can generate repeatable results and distinguish compounds that have minor
differences on inhibition activity. RXRα, RXRβ, PPARγ and LXRβ give the poorest
performance on the assay.
The cell number is an important condition needed to be determined for our assay.
When cells were too few, a small amount of beta-lactamase would be produced in each
well. The signal generated would be relatively low after subtracting the basal signal (cellfree wells), and it would be more sensitive to background signal and thus produce a big
error bar. When cells seeded in each well are too many they would reach confluence after
16 hours incubation which would affect the health of cells and the performance of the
assay. With the lowest number of cells seeded in each well the highest response ratio was
generated with the biggest error bars (Figure 3-3). When the cell number increased the
response ratio decreased a little but with lower error bars. Images were taken after 16
hours incubation show that the cells were already confluent for the wells that seeded 30k
cells. We finally choose to use 20k cells per well for GR, VDR, FXR and PPARγ, 10k
cells per well for RXRα, RXRβ, LXRα and LXRβ for the following assays because at
this density cells would not reach confluence in the plates and gave relatively higher
positive to negative window with lower error bars.
To determine the best substrate incubation time for this assay, plates were read at
interval times after loading substrate (Figure 3-3). The response ratio window was
increasing after substrate was loaded until after two hours. The signal window remained
stable for at least 5 hours for GR, RXRα, RXRβ, LXRα and LXRβ. For VDR the signal
remained for 3 hours, while for FXR and PPARγ the signal window started to decrease
after 2 hours. This means we could read the data in this time range that the signal window
reached highest value and remained stable after substrate were loaded. We finally chose
the substrate loading time of 1 hour for PPARγ, 1.5 hours for VDR, RXRα and RXRβ, 2
hours for GR, FXR, LXRα and LXRβ in the following assay.
Since this assay will read the fluorescence intensity, we have to use the black wall,
clear-bottom plates for seeding the cells. However, HEK 293 cell is not easy to attach on
normal plates. Poly-D-Lysine coated plates which helped the cells to attach could be used
for the assay instead. It is necessary to test whether Poly-D-Lysine would have any
negative affect on cell growth and assay performance before Poly-D-Lysine plates were
used in the compound assay. The assay performance in both kinds of plates was tested to
generate the best condition for each cell line in the assay. Under the optimized conditions
generated (cell number and substrate loading time) in the previous sections, assays with
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Figure 3-3. Assay performance with different cell density and substrate loading
time. Response ratio (pos ⁄neg) generated by certain cell numbers at certain time after
substrate loaded. The error bars stand for ± s.d.
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each cell line were performed in both regular plates and Poly-D-Lysine coated plates. The
Z’ factor which is a statistical parameter measures the quality of a particular assay in
high-throughput screening showed that all the cell lines perform better in Poly-D-Lysine
plates except RXRβ because it generated a very high 460 nm⁄530 nm ratio for
unstimulated wells (cells with DMSO only) (Table 3-1). The images taken after 16 hours
incubation showed that cells grew as healthy as in regular plates and even denser in PolyD-Lysine coating plates than the regular plates even though the cell density is the same
when seeded (supplementary Figure A-1). However, the pin would damage the coating if
it touched the bottom when transferring compounds. Cells couldn’t grow on the coating
damaged area. Fortunately, the readout was not affected by those tiny damaged coating
areas of the plates. So, Poly-D-Lysine coating plates would be used to screen the
compounds for GR, VDR, RXRα, FXR, PPARγ, LXRα and LXRβ while regular noncoating plates would be used for RXRβ.
The tool used to dispense cells in the 384-well plates was also very important to
generate stable and acceptable assay results. This is because the amount of expressed
beta-lactamase in each well is dependent on the amount of cells seeded in each well. 384channel VPrep® pipette and Matix WellMate at 3 different dispense speeds were tested
for seeding equal amounts of HEK 293T cells. It turned out that WellMate at middle
speed can dispense cells equally and evenly in each well (data not shown). 16-well
automatic hand pipette was used to load substrate. HEK 293T cells are notorious for not
sticking well on plates. The mechanical force generated when using WellMate or VPrep
dispensing the substrate would destroy the even distribution of cells which results in
inconsistent reading of fluorescence intensity.
EC50 Determination
EC50 of the agonist is variable in a small range with different experimental conditions.
We tested the EC50 of the agonist for each nuclear receptor in our experiment under the
optimized condition for our compound assays. The agonists used are Dexamethasone for
GR, Calcitriol (1α, 25-dihydroxyvitamin D3) for VDR, 9-cis-retinoic acid for RXRα and
RXRβ, GW4064 for FXR, Rosiglitazone for PPARγ, TO901317 for LXRα and LXRβ.
All these agonists were the most potent for its target among the reported agonists.
The agonists used in this assay were recommended by Invitrogen except GW4064.
Another agonist for FXR, Chenodeoxycholic acid (CDCA) was used first for a dose
response experiment. It turns out that at the reported maximum concentration of
stimulation, the transactivity of FXR couldn’t be saturated. After increased the
concentration applied it showed cytotoxicity to the cell line (supplementary Figure A-2).
When GW4064 was applied to stimulate FXR, a perfect dose-response curve was
generated.
After graphing the dose-response curve, the EC50 was determined (Figure 3-4). They
were 1.09 nM of Dexamethasone for GR, 0.23 nM of Calcitriol for VDR, 15.7 nM and
16.48 nM of 9-cis-retinoic acid for RXRα and RXRβ respectively, 40.05 nM of GW4064
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Table 3-1. Z’ factor of assay in regular and Poly-D-Lysine plates for each cell line.
GR

VDR

RXRα

RXRβ

FXR

PPARγ

LXRα

LXRβ

regular

0.73

0.54

0.74

0.76

0.82

0.53

0.85

0.73

P-D-L

0.90

0.88

0.75

0.53

0.81

0.74

0.88

0.84
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Figure 3-4. Dose response of the nuclear receptor to its primary agonist. The EC50
generated in dose-response were 1.09 nM of Dexamethasone for GR, 0.23 nM of
Calcitriol for VDR, 15.7 nM and 16.48 nM of , 9-cis-retinoic acid for RXRα and RXRβ
respectively, 40.05 nM of GW4064 for FXR, 6.32 nM of Rosiglitazone for PPARγ, 23.04
nM and 87.52 nM of TO901317 for LXRα and LXRβ respectively. The error bars stand
for ± s. d.
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for FXR, 6.32 nM of Rosiglitazone for PPARγ, 23.04 nM and 87.52 nM of TO901317 for
LXRα and LXRβ respectively. They were consistent with the reported data. With the
generated dose-response curve, EC80 could also be determined. A final concentration
between EC50 and EC80 was used to stimulate the nuclear receptor during the compound
assay because any inhibition on the agonist induced transactivity in the range between
EC50 and EC80 will be detected.
Selecting Specific Compounds
92 compounds identified as PXR antagonists without cytotoxicity in HepG cells
(Wenwei Lin, unpublished data) were applied for this beta-lactamase reporter gene assay
under optimized conditions for specificity using cell lines carrying GR, VDR, RXRα,
RXRβ, FXR, PPARγ, LXRα and LXRβ respectively.
Z’ factor was calculated for each plate in the compounds assay (Figure 3-5). The Z’
value showed that all of them are greater than 0.6, which means the assay results are
acceptable. Z’ values for GR and VDR are around 0.9 and quite stable among each assay
plate. This result is consistent with the one in the section on assay optimization (Figure
3- 3). Both of them indicate that among the eight cell lines GR and VDR are the ones that
can generate most reliable results.
The assay showed that at very low concentration all compounds don’t have any
inhibition activity on the transcriptional activity of the eight nuclear receptors (data not
shown). However, these compounds are very potent to PXR (Wenwei Lin, unpublished
data). This means when administrating at a low concentration, all compounds are
relatively specific to PXR.
Among these compounds 21 hits were selected as specific PXR antagonists (Table
3-2). These compounds, such as SJ000129508, SJ000168394, SJ000200343,
SJ000254150 etc, didn’t show any inhibition activity for eight nuclear receptors
(inhibition activity below 20% at 40 μM) but were potent inhibitors for PXR (Figure
3-6). With a large concentration range, they are specific inhibitors exclusively for PXR.
We may perform SAR study to identify the structure similarity for these selected PXR
antagonists in the future. Furthermore, the molecular mechanism of these antagonists to
PXR needs to be unraveled by using animal models.
There are two compounds, SJ000025162 and SJ000302340 which showed inhibition
activity to all the 8 cell lines. However, we were not sure whether the inhibition activity
is due to its real antagonistic effect to the transcriptional activity of the nuclear receptors
or the cytotoxicity to the cell lines since we noticed the cells of some wells were very
sick even dead after 16 hours incubation with compounds administrated (Figure 3-7). To
test if these compounds were toxic to the cells, cytotoxicity assay was performed on HEK
293T cell line 24 hours incubation (Wenwei Lin, unpublished data). When SJ000302340
showed inhibition activity to the nuclear receptors it showed cytotoxicity to HEK 293T
cells as well. This suggested that whether the compound was antagonist for the nuclear
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Figure 3-5. Z’ factor of each assay plate. Compound assays were performed in
triplicate. 92 compounds distributed in 3 master solution plates were tested.
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Table 3-2. The antagonistic effect of putative hPXR antagonists on various nuclear
receptors.
Compounds
SJ000232984
SJ000274586
SJ000272971
SJ000275692
SJ000232052
SJ000265390
SJ000254921
SJ000254150
SJ000278772
SJ000271955
SJ000241120
SJ000240467
SJ000233799
SJ000249508
SJ000168475
SJ000057958
SJ000289918
SJ000129508
SJ000299592
SJ000176510
SJ000150475
SJ000134698
SJ000156455
SJ000199270
SJ000200343
SJ000158493
SJ000202840
SJ000290832
SJ000168394
SJ000204230
SJ000147225
SJ000057839
SJ000051863
SJ000052850
SJ000056684
SJ000057241
SJ000057286
SJ000057310
SJ000057626
SJ000057838
SJ000043424
SJ000044857

GR

VDR

RXRα

RXRβ

23

FXR

PPARγ

LXRα

LXRβ

Table 3-2 (continued).
Compounds
SJ000044880
SJ000045006
SJ000045276
SJ000049443
SJ000050295
SJ000051829
SJ000041640
SJ000041641
SJ000041650
SJ000041678
SJ000041695
SJ000041708
SJ000041720
SJ000041727
SJ000009149
SJ000013041
SJ000013324
SJ000024528
SJ000025162
SJ000026086
SJ000031772
SJ000106379
SJ000107890
SJ000101695
SJ000097801
SJ000080343
SJ000079998
SJ000076745
SJ000076741
SJ000076593
SJ000076585
SJ000076583
SJ000075847
SJ000075766
SJ000075332
SJ000075197
SJ000072854
SJ000071406
SJ000065778
SJ000065777
SJ000065773
SJ000061292
SJ000059479

GR

VDR

RXRα

RXRβ

24

FXR

PPARγ

LXRα

LXRβ

Table 3-2 (continued).
Compounds
SJ000059461
SJ000059404
SJ000059367
SJ000023063
SJ000302340
CMLD001455
CMLD001197

GR

VDR

RXRα

RXRβ

FXR

PPARγ

LXRα

LXRβ

Note: At the highest concentration administrated (40 μM), compounds that show less
than 20% inhibition activity are colored white, 20% to 50% are tan, 50% to 80% are
orange, and above 80% are red. Compounds colored white for all eight NRs are hits for
the beta-lactamase reporter assay.
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Figure 3-6. Specific PXR antagonists. The compounds didn’t affect the transcriptional
activity of the 8 nuclear receptors. They showed inhibition activity to PXR even at low
concentration. The error bars stand for ± s. d.
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Figure 3-7. Compounds that showed inhibition activity to all cell lines in the assay.
SJ000025162 and SJ000302340 showed inhibition activity to all eight nuclear receptors.
SJ000025162 is 40% toxic to cells at 40 μM. It’s not toxic up to 10μM. It probably inhibited
the transcriptional activity of at least some of the eight nuclear receptors. SJ000302340 is
toxic to HEK 293T cell above 10 μM. The inhibition is probably due to its cytotoxicity. The
error bars stand for ± s. d.
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receptors remains unknown. Compound SJ000025162 showed high inhibition activity but it
was only 20% toxic to HEK 293T cells at the 40 μM. It suggested that this compound was an
antagonist for all the nuclear receptors in this assay.
Most of these compounds can inhibit the activity of RXRβ (60) and PPARγ (47). It might
suggest some structure similarity of the RXRβ, PPARγ and PXR. Among the 47 compounds
that showed inhibition activity to PPAR γ most of them are very potent just like their
inhibition ability to PXR. Through this reporter gene assay, not only did we identified the
compounds that are specific to PXR we also got the information of their effects to other eight
nuclear receptors. It can be used to identify the antagonists for other nuclear receptors as well.
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APPENDIX. SUPPLEMENTAL DATA FOR CHAPTER 3

Figure A-1. Cell growth on different assay plates. 10,000 per well LXRα cells were
seeded in Poly-D-Lysine coated and regular black-wall, clear bottom plate respectively.
Images were taken after 16 hours incubation.
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Figure A-2. Dose response curve of CDCA to FXR. A. When using reported maximum
stimulation concentration of CDCA to FXR, the activation activity can not be saturated. B.
After increased the concentration of CDCA used to stimulate FXR, the agonist showed
cytocoxicity.
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